SEHK Growth Companies With High Insider Ownership August 2024

In this article:

The Hong Kong market has been navigating a challenging landscape, with the Hang Seng Index experiencing a slight decline amid weak manufacturing data and broader economic concerns. Despite these headwinds, certain growth companies with high insider ownership continue to stand out as potentially resilient investments. In this context, stocks with substantial insider ownership often signal strong confidence from those closest to the company, which can be particularly appealing in uncertain times.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

18.8%

104.1%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Fenbi (SEHK:2469)

31.1%

42.8%

Adicon Holdings (SEHK:9860)

22.4%

28.3%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

79.3%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

74.5%

Ocumension Therapeutics (SEHK:1477)

23.3%

93.7%

Beijing Airdoc Technology (SEHK:2251)

28.6%

83.9%

Click here to see the full list of 54 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

LifeTech Scientific

Simply Wall St Growth Rating: ★★★★☆☆

Overview: LifeTech Scientific Corporation develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases globally, with a market cap of HK$7.22 billion.

Operations: The company's revenue segments include CN¥495.67 million from the Structural Heart Diseases Business, CN¥707.11 million from the Peripheral Vascular Diseases Business, and CN¥64.40 million from the Cardiac Pacing and Electrophysiology Business.

Insider Ownership: 16%

Earnings Growth Forecast: 20.5% p.a.

LifeTech Scientific, a growth company with high insider ownership, is forecasted to grow earnings at 20.55% annually, outpacing the Hong Kong market's 11.2%. Recent amendments to its bylaws and promising Phase II clinical study results for its IBS? Coronary Scaffold highlight ongoing innovation and regulatory progress. Despite lower-than-benchmark return on equity forecasts (10.8%), the company's strong revenue growth (16.8% per year) underscores its potential in advancing medical technology solutions globally.

SEHK:1302 Ownership Breakdown as at Aug 2024
SEHK:1302 Ownership Breakdown as at Aug 2024

MGM China Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: MGM China Holdings Limited is an investment holding company that develops, owns, and operates gaming and lodging resorts in the Greater China region, with a market cap of HK$44.23 billion.

Operations: The company's revenue primarily comes from its casinos and resorts, generating HK$24.68 billion.

Insider Ownership: 10%

Earnings Growth Forecast: 18.3% p.a.

MGM China Holdings, with substantial insider ownership, has become profitable this year and is forecasted to grow earnings at 18.3% annually, surpassing the Hong Kong market's 11.2%. The company recently issued $500 million in senior notes due 2031 to repay its revolving credit facility, enhancing financial flexibility. Trading at a significant discount to its fair value estimate and with a very high return on equity forecast (88.5%), MGM China shows strong growth potential despite moderate revenue growth projections (8.4% per year).

SEHK:2282 Earnings and Revenue Growth as at Aug 2024
SEHK:2282 Earnings and Revenue Growth as at Aug 2024

Adicon Holdings

Simply Wall St Growth Rating: ★★★★★☆

Overview: Adicon Holdings Limited operates medical laboratories in the People’s Republic of China and has a market cap of HK$7.08 billion.

Operations: Adicon Holdings Limited generates revenue from healthcare facilities and services amounting to CN¥3.30 billion.

Insider Ownership: 22.4%

Earnings Growth Forecast: 28.3% p.a.

Adicon Holdings, with high insider ownership, is forecasted to grow earnings significantly at 28.3% annually and revenue at 14.3% per year, outpacing the Hong Kong market. The company has initiated a share repurchase program authorized to buy back up to 10% of its issued share capital, potentially boosting net asset value and earnings per share. Recent board changes include appointing Mr. ZHOU Mintao as a non-executive director and chairman of the strategy committee.

SEHK:9860 Earnings and Revenue Growth as at Aug 2024
SEHK:9860 Earnings and Revenue Growth as at Aug 2024

Summing It All Up

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:1302 SEHK:2282 and SEHK:9860.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Advertisement